6:57 PM
Jul 30, 2008
 |  BC Extra  |  Company News

Cytochroma, Mitsubishi Tanabe in CTA018 deal

Cytochroma (Markham, Ontario) granted Mitsubishi Tanabe Pharma (Tokyo:4508; Osaka:4508) an exclusive license to develop and commercialize CTA018 and follow-on compounds in the U.S. and Asia. The vitamin D analog is expected to start Phase II testing to treat secondary hyperparathyroidism (SHPT) in...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >